PRE-REGISTER for this Workshop
|12:30 - 13:15
Despite a few decades of proteomics research and the apparent discovery of multiple protein biomarkers to support the diagnosis and treatment of patients, the number of protein biomarkers that have been developed to the stage of being used routinely is disappointingly low. So, it's clear that whilst there’s huge interest in the field of research for development of new protein biomarkers and major drivers for this to happen: including the pharmaceutical industry’s need to better stratify patients for effective treatment, as yet biomarker development and delivery is proving very challenging. Why is this?
By enabling rapid assay development and evaluation, SRM/MRM on triple quadrupole mass spectrometers holds huge potential as a platform for the development of specific and sensitive 'biomarker signatures' comprising multiple proteins. However, once such prototype signatures are developed can they be clinically validated and then delivered to a clinical test environment? Addressing this current bottleneck may be dependent on the implementation of robust and reliable workflows with methods that are easy, quick and inexpensive and may be automated.
For Research Use Only. Not for use in diagnostic procedures.